Please assess the completion status of the following clinical trial:

Trial Title: Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Rheumatoid Arthritis~* Current treatment with either etanercept or adalimumab for at least 12 weeks prior to randomization~* Disease Activity Score (DAS) C-reactive Protein (CRP) 28 ≥ 4.4~* Treatment with concomitant Disease-Modifying Anti-Rheumatic Drugs (DMARDs) is permitted but not required as described below:~  1. Methotrexate - maximum dose of 25 mg per os (PO), intra-muscular (IM), or SQ weekly.~ 2. Leflunomide - maximum dose of 20 mg PO daily.~ 3. Sulfasalazine - maximum dose of 1,500 mg PO twice daily.~ 4. Hydroxychloroquine - maximum dose of 400 mg PO daily.~* If taking DMARD(s), subjects must be on stable doses for at least 12 weeks prior to randomization.~* If treated with prednisone (or equivalent corticosteroid), on a stable dose of \<= 10 mg/day for 28 days prior to randomization.~* Agree to use appropriate form of contraception. More information on this criterion can be found in the protocol.~Exclusion Criteria:~* Diagnosis of another autoimmune disease likely to require immunosuppression. More information on this criterion can be found in the protocol.~* Failing treatment with etanercept if previously treated with adalimumab~* Failing treatment with adalimumab if previously treated with etanercept~* Intraarticular injection within 4 weeks prior to randomization~* Concomitant use of DMARDs other than those described in Inclusion Criteria within 12 weeks of randomization.~* Concurrent use of any biologic agent other than etanercept or adalimumab~* Concomitant immunosuppressive therapy other than the Disease-Modifying Anti-Rheumatic Drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids specified in the protocol~* Presence of open leg ulcers~* Chronic or persistent infection that may be worsened by immunosuppressive treatment. More information on this criterion can be found in the protocol.~* Active infection or severe infections requiring hospitalization or treatment with intravenous antibiotics, antivirals, or antifungals within 30 days prior to randomization~* History of positive Purified Protein Derivative (PPD) or chest x-ray findings indicative of prior tuberculosis infection~* Any medical condition or treatment that, in the opinion of the investigator, would put the subject at risk by participation in the study~* History of malignancy. More information on this criterion can be found in the protocol.~* Certain abnormal laboratory values. More information on this criterion can be found in the protocol.~* Investigational biological or chemical agents within 4 weeks prior to randomization.~* History of drug or alcohol abuse within a year prior to randomization~* Treatment with natalizumab, rituximab, or another B-cell depleting therapy within a year prior to randomization~* Treatment with infliximab, abatacept, tocilizumab, golimumab, or certolizumab pegol within 12 weeks prior to randomization.~* Known allergy or hypersensitivity to study products~* Any psychiatric disorder that prevents the participant from providing informed consent~* Inability to follow protocol instructions~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab / Adalimumab Placebo (Type: EXPERIMENTAL): 1 sub-cutaneous (SQ) injection of adalimumab or 1 SQ injection of placebo will be given in a blinded and alternating fashion for a total of 12 weeks
- Etanercept (Type: EXPERIMENTAL): Participants will receive 1 SQ injection of etanercept each week for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).